Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 2026
Optimizing treatment strategies for early-onset mucinous adenocarcinoma of the colon: A SEER database analysis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Perrone Cameron, Emile Sameh Hany, Lopez Christopher, Barnes Spencer, Wignakumar Anjelli, Bilotti Matthew, Wexner Steven D
Аннотация
BACKGROUND: Colorectal mucinous adenocarcinoma (MAC) is challenging due to its unique pathophysiology and increasing incidence in younger populations. Treatment guidelines for early-onset MAC remain unclear, with clinical decisions often based on extrapolated data from classical adenocarcinoma. We aimed to assess the association between the extent of surgical resection and systemic therapy in patients with early-onset colonic MAC and survival.
METHODS: Retrospective cohort analysis of patients aged 20-50 with stage II-III colonic MAC using the SEER database (2000-2020). We evaluated overall survival (OS) and cancer-specific survival (CSS) based on surgical resection (segmental vs. extended) and systemic therapy, using Kaplan-Meier and Cox regression analyses.
RESULTS: The cohort included 2553 patients (58.5% male; mean age 42.7 years). Segmental resection was performed in 27.6%. Extended resection was more commonly performed in right-sided and stage III disease. Systemic therapy was administered to 62.1%, predominantly for stage III disease with unfavourable tumour features. Systemic therapy was associated with improved restricted mean 5-year CSS (51.7 vs. 47.8 months, p = 0.041) and OS (51.1 vs. 45.9 months, p = 0.008) in stage III, but not stage II, disease. Extended resection was associated with a modest survival benefit for CSS (56.5 vs. 54.3 months, p = 0.027) and OS (56.0 vs. 53.3 months, p = 0.007) in stage II, but not stage III, disease.
CONCLUSION: Systemic therapy was associated with a significant survival benefit in patients with stage III early-onset MAC, supporting its role as a cornerstone of treatment despite the histology's presumed chemoresistance.
METHODS: Retrospective cohort analysis of patients aged 20-50 with stage II-III colonic MAC using the SEER database (2000-2020). We evaluated overall survival (OS) and cancer-specific survival (CSS) based on surgical resection (segmental vs. extended) and systemic therapy, using Kaplan-Meier and Cox regression analyses.
RESULTS: The cohort included 2553 patients (58.5% male; mean age 42.7 years). Segmental resection was performed in 27.6%. Extended resection was more commonly performed in right-sided and stage III disease. Systemic therapy was administered to 62.1%, predominantly for stage III disease with unfavourable tumour features. Systemic therapy was associated with improved restricted mean 5-year CSS (51.7 vs. 47.8 months, p = 0.041) and OS (51.1 vs. 45.9 months, p = 0.008) in stage III, but not stage II, disease. Extended resection was associated with a modest survival benefit for CSS (56.5 vs. 54.3 months, p = 0.027) and OS (56.0 vs. 53.3 months, p = 0.007) in stage II, but not stage III, disease.
CONCLUSION: Systemic therapy was associated with a significant survival benefit in patients with stage III early-onset MAC, supporting its role as a cornerstone of treatment despite the histology's presumed chemoresistance.